FDA to Survey Healthcare Professionals on Opioid Promotion

The FDA plans to survey healthcare professionals to better understand how prescribers are influenced by prescription drug promotions.

The agency wants to learn how familiar healthcare professionals are with the FDA’s prescription drug approval process, how it can influence their prescribing decisions, and how knowledgeable they are in clinical trial data and design and their place in drug promotions.

The agency plans to process surveys for 700 primary care physicians, 600 specialists, 350 nurse practitioners and 350 physician assistants.